What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI)

Regulatory Toxicology and Pharmacology

Volumn 60, Issue 3, 2011, Pages 290-295

  M'Kada, Helmi ^a,e   Munteanu, Mona ^b   Perazzo, Hugo ^a   Ngo, Yen ^b   Ramanujam, Nittia ^a   Imbert Bismut, Françoise ^a,e   Ratziu, Vlad ^a   Bonnefont Rousselot, Dominique ^a,e,f   Souberbielle, Bernard ^c   Schuppe Koistinen, Ina ^d   Poynard, Thierry ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b Biopredictive   (France)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d Groupe Hospitalier Pitié Salpêtrière ^*

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

Author keywords

ALT; Biomarkers; DILI; Hy's law; Limit of the normal; Liver necrosis; Reference values; Temple criteria

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HEPATITIS; HUMAN; LIVER EXAMINATION; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TOXIC HEPATITIS;

ALANINE TRANSAMINASE; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; REFERENCE VALUES;

EID: 79960149216     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2011.04.002     Document Type: Article

References (26)

1. Athyros V.G., Tziomalos K., Gossios T.D., Griva T., Anagnostis P., Kargiotis K., Pagourelias E.D., Theocharidou E., Karagiannis A., Mikhailidis DP. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the greek atorvastatin and coronary heart disease evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010, 376:1916-1922. GREACE Study Collaborative Group.
2. Castera L., Pinzani M. Non-invasive assessment of liver fibrosis: are we ready?. Lancet 2010, 375:1419-1420.
3. Dutta A., Saha C., Johnson C.S., Chalasani N. Variability in the upper limit of normal for serum alanine aminotransferase levels: a statewide study. Hepatology 2009, 50:1957-1962.
4. Ferard G., Piton A., Messous D., Imbert-Bismut F., Frairi A., Poynard T., et al. Intermethod calibration of alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) results: application to Fibrotest and Actitest scores. Clin. Chem. Lab Med. 2006, 44:400-406.
5. Fontana R.J., Seeff L.B., Andrade R.J., Björnsson E., Day C.P., Serrano J., Hoofnagle J.H. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010, 52:730-742.
6. Halfon P., Imbert-Bismut F., Messous D., Antoniotti G., Benchetrit D., Cart-Lamy P., Delaporte G., Doutheau D., Klump T., Sala M., Thibaud D., Trepo E., Thabut D., Myers R.P., Poynard T. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp. Hepatol. 2002, 1:3.
7. Imbert-Bismut F., Messous D., Thibaut V., Myers R.B., Piton A., Thabut D., et al. Intralaboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin. Chem. Lab Med. 2004, 42:323-333.
8. Kim H.C., Nam C.M., Jee S.H., Han K.H., Oh D.K., Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004, 328:983.
9. Lee J.K., Shim J.H., Lee H.C., Lee S.H., Kim K.M., Lim Y.S., Chung Y.H., Lee Y.S., Suh D.J. Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology 2010, 51:1577-1583.
10. Myara A., Guéchot J., Imbert-Bismut F., Lasnier E., Piton A., Voitot H., Férard G. Harmonization of liver enzyme results: calibration for aminotransferases and gamma glutamyltransferase. J. Hepatol. 2004, 41:501-502.
11. Naveau S., Gaudé G., Asnacios A., Agostini H., Abella A., Barri-Ova N., Dauvois B., Prévot S., Ngo Y., Munteanu M., Balian A., Njiké-Nakseu M., Perlemuter G., Poynard T. Diagnostic and prognostic values of non-invasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009, 49:97-105.
12. NCSS Hintze.J.L. User Guide 2007, Number cruncher statistical systems software NCSS, Kaysville, Utah 2007.
13. Ngo Y., Munteanu M., Messous D., Charlotte F., Imbert-Bismut F., Thabut D., Lebray P., Thibault V., Benhamou Y., Moussalli J., Ratziu V., Poynard T. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin. Chem. 2006, 52:1887-1896.
14. Ngo Y., Benhamou Y., Thibault V., Ingiliz P., Munteanu M., Lebray P., Thabut D., Morra R., Messous D., Charlotte F., Imbert-Bismut F., Bonnefont-Rousselot D., Moussalli J., Ratziu V., Poynard T. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (Fibrotest-Actitest) and viral load. PlosOne 2008, 3:e2573.
15. Ozer J.S., Chetty R., Kenna G., Koppiker N., Karamjeet P., Li D., Palandra J., Lanevschi A., Souberbielle B.E., Ramaiah S. Recommendations to qualify biomarker candidates of drug-induced liver injury. Biomark Med. 2010, 4:475-483.
16. Ozer J.S., Chetty R., Kenna G., Palandra J., Zhang Y., Lanevschi A., Koppiker N., Souberbielle B.E., Ramaiah S.K. Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury. Regul. Toxicol. Pharmacol. 2010, 56:237-246.
17. Piton A., Poynard T., Imbert-Bismut F., Khalil L., Delattre J., Pelissier E., Sansonetti N., Opolon P. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 1998, 27:1213-1219.
18. Poynard T. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy. J. Hepatol. 2011, 54:586-587.
19. Poynard T., Ratziu V., Naveau S., Thabut D., Charlotte F., Messous D., Capron D., Abella A., Massard J., Ngo Y., Munteanu M., Mercadier A., Manns M., Albrecht J. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp. Hepatol. 2005, 4:10.
20. Poynard T., Munteanu M., Ngo Y., Castera L., Halfon P., Ratziu V., Imbert-Bismut F., Thabut D., Bourliere M., Cacoub P., Messous D., de Ledinghen V. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Gastroenterol. Clin. Biol. 2010, 34:388-396.
21. Poynard T., Lebray P., Ingiliz P., Varaut A., Varsat B., Ngo Y., Norha P., Munteanu M., Drane F., Messous D., Bismut F.I., Carrau J.P., Massard J., Ratziu V., Giordanella J.P. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol. 2010, 10:40.
22. Prati D., Taioli E., Zanella A., Della Torre E., Butelli S., Del Vecchio E., Vianello L., Zanuso F., Mozzi F., Milani S., Conte D., Colombo M., Sirchia G. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med. 2002, 2(137):1-10.
23. Ratziu V., Charlotte F., Heurtier A., Gombert S., Giral P., Bruckert E., Grimaldi A., Capron F. LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128:1898-1906.
24. Watkins P.B., Seligman P.J., Pears J.S., Avigan M.I., Senior J.R. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 2008, 48:1680-1689.
25. Weil J.G., Bains C., Linke A., Clark D.W., Stirnadel H.A., Hunt C.M. Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease. Regul. Toxicol. Pharmacol. 2008, 52:85-88.
26. http://www.fda.gov.